{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T14:52:22Z","timestamp":1793371942810,"version":"4.5.0"},"reference-count":98,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T00:00:00Z","timestamp":1756252800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Melanoma frequently develops bone metastases, leading to skeletal-related events and poor survival. The tumor microenvironment (TME) plays a pivotal role in melanoma progression, bone metastasis, and immunotherapy resistance. Key immunosuppressive cells including myeloid-derived suppressor cells (MDSCs), tumor-associated macrophages (TAMs), regulatory T cells (Tregs), and cancer-associated fibroblasts (CAFs) promote immune evasion and osteolytic bone destruction via RANKL-dependent and -independent mechanisms. Immune checkpoint inhibitors (ICIs), including anti-CTLA-4 and anti-PD-1\/PD-L1 therapies, have revolutionized melanoma treatment, yet resistance remains common due to TME immunosuppression. Emerging strategies, such as combination therapies, aim to enhance efficacy by reshaping the TME. This review synthesizes current knowledge on TME-driven immunosuppression, bone metastasis mechanisms, and immunotherapeutic advancements, offering insights into overcoming resistance and improving patient outcomes.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1608215","type":"journal-article","created":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T05:18:43Z","timestamp":1756271923000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":14,"title":["Immunosuppressive tumor microenvironment and advance in immunotherapy in melanoma bone metastasis"],"prefix":"10.3389","volume":"16","author":[{"given":"Yiqun","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weimin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2022.03.008","article-title":"European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics: Update 2022","volume":"170","author":"Garbe","year":"2022","journal-title":"Eur J Cancer"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.32604\/or.2024.055449","article-title":"Melanoma-derived extracellular vesicles transfer proangiogenic factors","volume":"33","author":"Wilczak","year":"2025","journal-title":"Oncol Res"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-023-00795-3","article-title":"Global incidence, mortality, risk factors and trends of melanoma: A systematic analysis of registries","volume":"24","author":"Huang","year":"2023","journal-title":"Am J Clin Dermatol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"100877","DOI":"10.1016\/j.neo.2023.100877","article-title":"Identification and characterization of circular RNAs as novel putative biomarkers to predict anti-PD-1 monotherapy response in metastatic melanoma patients - Knowledge from two independent international studies","volume":"37","author":"Zhou","year":"2023","journal-title":"Neoplasia"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/jso.27731","article-title":"Factors associated with skeletal-related events in patients with bone metastatic melanoma: A retrospective study of 481 patients","volume":"130","author":"Shimizu","year":"2024","journal-title":"J Surg Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.3618","article-title":"Understanding the bone in cancer metastasis","volume":"33","author":"Fornetti","year":"2018","journal-title":"J Bone Miner Res"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1507283","article-title":"CD8(+) T cell exhaustion in the tumor microenvironment of breast cancer","volume":"15","author":"Xie","year":"2024","journal-title":"Front Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.32604\/or.2025.063843","article-title":"Tumor vaccines for Malignant melanoma: progress, challenges, and future directions","volume":"33","author":"Luo","year":"2025","journal-title":"Oncol Res"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.32604\/or.2024.043987","article-title":"mRNA vaccines: a new era in vaccine development","volume":"32","author":"Chandra","year":"2024","journal-title":"Oncol Res"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2022.04.018","article-title":"European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2022","volume":"170","author":"Garbe","year":"2022","journal-title":"Eur J Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01206-X","article-title":"Immune checkpoint inhibitors in melanoma","volume":"398","author":"Carlino","year":"2021","journal-title":"Lancet"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21218359","article-title":"The influence of tumor microenvironment on immune escape of melanoma","volume":"21","author":"Simiczyjew","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26146778","article-title":"Tumor microenvironment in melanoma-characteristic and clinical implications","volume":"26","author":"Sikorski","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e37060","article-title":"Eliminating a barrier: Aiming at VISTA, reversing MDSC-mediated T cell suppression in the tumor microenvironment","volume":"10","author":"Deng","year":"2024","journal-title":"Heliyon"},{"key":"B15","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/s41392-021-00670-9","article-title":"Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer","volume":"6","author":"Li","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004384","article-title":"STAT3 inhibitor Napabucasin abrogates MDSC immunosuppressive capacity and prolongs survival of melanoma-bearing mice","volume":"10","author":"Bitsch","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1172\/JCI170762","article-title":"Enhancing immunotherapy response in melanoma: myeloid-derived suppressor cells as a therapeutic target","volume":"133","author":"Ozbay Kurt","year":"2023","journal-title":"J Clin Invest"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-17-0348","article-title":"et al: CCR5(+) myeloid-derived suppressor cells are enriched and activated in melanoma lesions","volume":"78","author":"Blattner","year":"2018","journal-title":"Cancer Res"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.32604\/or.2023.029697","article-title":"Glycogen metabolism-mediated intercellular communication in the tumor microenvironment influences liver cancer prognosis","volume":"32","author":"Zhang","year":"2024","journal-title":"Oncol Res"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.7150\/thno.50928","article-title":"Tumor microenvironment remodeling and tumor therapy based on M2-like tumor associated macrophage-targeting nano-complexes","volume":"11","author":"Han","year":"2021","journal-title":"Theranostics"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-020-02616-6","article-title":"Pro-tumorigenic functions of macrophages at the primary, invasive and metastatic tumor site","volume":"69","author":"Nasrollahzadeh","year":"2020","journal-title":"Cancer Immunol Immunother"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-13-1007","article-title":"The immune microenvironment confers resistance to MAPK pathway inhibitors through macrophage-derived TNF\u03b1","volume":"4","author":"Smith","year":"2014","journal-title":"Cancer Discov"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-004605","article-title":"Tumor-associated Tregs obstruct antitumor immunity by promoting T cell dysfunction and restricting clonal diversity in tumor-infiltrating CD8+ T cells","volume":"10","author":"Noyes","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.940052","article-title":"Exhaust the exhausters: Targeting regulatory T cells in the tumor microenvironment","volume":"13","author":"McRitchie","year":"2022","journal-title":"Front Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00014","article-title":"Recent advances in targeting CD8 T-cell immunity for more effective cancer immunotherapy","volume":"9","author":"Durgeau","year":"2018","journal-title":"Front Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13184722","article-title":"Adoptive NK cell therapy: A promising treatment prospect for metastatic melanoma","volume":"13","author":"van Vliet","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13061363","article-title":"Targeting NK cells to enhance melanoma response to immunotherapies","volume":"13","author":"Lee","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2019.08.002","article-title":"Unraveling the crosstalk between melanoma and immune cells in the tumor microenvironment","volume":"59","author":"Marzagalli","year":"2019","journal-title":"Semin Cancer Biol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"3655595","DOI":"10.1155\/2022\/3655595","article-title":"Derived multiple allogeneic protein paracrine signaling (d-MAPPS)\u201d Enhances T cell-driven immune response to murine mammary carcinoma","volume":"2022","author":"Harrell","year":"2022","journal-title":"Anal Cell Pathol (Amst)"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.01196-24","article-title":"Regulation of IL-10 production in dendritic cells is controlled by the co-activation of TLR2 and Mincle by Lactiplantibacillus plantarum OLL2712","volume":"13","author":"Sakabe","year":"2025","journal-title":"Microbiol Spectr"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2018.04.025","article-title":"New peptide MY1340 revert the inhibition effect of VEGF on dendritic cells differentiation and maturation via blocking VEGF-NRP-1 axis and inhibit tumor growth in vivo","volume":"60","author":"Mo","year":"2018","journal-title":"Int Immunopharmacol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000832","article-title":"Skin dendritic cells in melanoma are key for successful checkpoint blockade therapy","volume":"9","author":"Prokopi","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-018-1993-2","article-title":"Defective levels of both circulating dendritic cells and T-regulatory cells correlate with risk of recurrence in cutaneous melanoma","volume":"21","author":"Tucci","year":"2019","journal-title":"Clin Transl Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22105283","article-title":"Influence of tumor microenvironment and fibroblast population plasticity on melanoma growth, therapy resistance and immunoescape","volume":"22","author":"Romano","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-18-0086","article-title":"Stromal fibroblasts mediate anti-PD-1 resistance via MMP-9 and dictate TGF\u03b2 Inhibitor sequencing in melanoma","volume":"6","author":"Zhao","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12061364","article-title":"Bad neighborhood: fibrotic stroma as a new player in melanoma resistance to targeted therapies","volume":"12","author":"Diazzi","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B37","doi-asserted-by":"publisher","first-page":"216906","DOI":"10.1016\/j.canlet.2024.216906","article-title":"MDSCs in bone metastasis: Mechanisms and therapeutic potential","volume":"592","author":"Li","year":"2024","journal-title":"Cancer Lett"},{"key":"B38","doi-asserted-by":"publisher","first-page":"4681","DOI":"10.1038\/s41467-025-59381-2","article-title":"Histone methyltransferase ASH1L primes metastases and metabolic reprogramming of macrophages in the bone niche","volume":"16","author":"Meng","year":"2025","journal-title":"Nat Commun"},{"key":"B39","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.molimm.2021.07.004","article-title":"Age-related expansion and increased osteoclastogenic potential of myeloid-derived suppressor cells","volume":"137","author":"Li","year":"2021","journal-title":"Mol Immunol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.568362","article-title":"The immunoregulatory role of myeloid-derived suppressor cells in the pathogenesis of rheumatoid arthritis","volume":"11","author":"Yan","year":"2020","journal-title":"Front Immunol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbo.2016.03.004","article-title":"The role of tumour-associated macrophages in bone metastasis","volume":"5","author":"Sousa","year":"2016","journal-title":"J Bone Oncol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.778078","article-title":"Macrophage-osteoclast associations: origin, polarization, and subgroups","volume":"12","author":"Sun","year":"2021","journal-title":"Front Immunol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.763846","article-title":"Cross talk between macrophages and cancer cells in the bone metastatic environment","volume":"12","author":"Batoon","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12041014","article-title":"Contribution of macrophages and T cells in skeletal metastasis","volume":"12","author":"Mendoza-Reinoso","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1159\/000489184","article-title":"Molecular regulation of bone metastasis pathogenesis","volume":"46","author":"Wu","year":"2018","journal-title":"Cell Physiol Biochem"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2015.08.010","article-title":"Myeloid-derived suppressor cells contribute to bone erosion in collagen-induced arthritis by differentiating to osteoclasts","volume":"65","author":"Zhang","year":"2015","journal-title":"J Autoimmun"},{"key":"B47","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/S0002-9440(10)61765-8","article-title":"Concurrent induction of lymphangiogenesis, angiogenesis, and macrophage recruitment by vascular endothelial growth factor-C in melanoma","volume":"159","author":"Skobe","year":"2001","journal-title":"Am J Pathol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0215(20000115)85:2%3C182::AID-IJC6%3E3.0.CO;2-M","article-title":"Macrophage infiltration correlates with tumor stage and angiogenesis in human Malignant melanoma: possible involvement of TNFalpha and IL-1alpha","volume":"85","author":"Torisu","year":"2000","journal-title":"Int J Cancer"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.166.11.6483","article-title":"Low-level monocyte chemoattractant protein-1 stimulation of monocytes leads to tumor formation in nontumorigenic melanoma cells","volume":"166","author":"Nesbit","year":"2001","journal-title":"J Immunol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1006\/bbrc.1999.1584","article-title":"High expression of macrophage migration inhibitory factor in human melanoma cells and its role in tumor cell growth and angiogenesis","volume":"264","author":"Shimizu","year":"1999","journal-title":"Biochem Biophys Res Commun"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1097\/00008390-200404000-00003","article-title":"Macrophage-derived soluble factor enhances melanoma inhibitory activity expression by uveal melanoma cells in vitro","volume":"14","author":"Callejo","year":"2004","journal-title":"Melanoma Res"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/8756-3282(91)90057-P","article-title":"Mechanisms of osteolytic bone destruction","volume":"12","author":"Mundy","year":"1991","journal-title":"Bone"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1097\/00003086-200004000-00013","article-title":"Review of cellular mechanisms of tumor osteolysis","volume":"373","author":"Clohisy","year":"2000","journal-title":"Clin Orthop Relat Res"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1006\/cyto.1999.0614","article-title":"Autocrine and paracrine regulation by cytokines and growth factors in melanoma","volume":"12","author":"L\u00e1z\u00e1r-Moln\u00e1r","year":"2000","journal-title":"Cytokine"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1007\/BF02411252","article-title":"Bone acid phosphatase: tartrate-resistant acid phosphatase as a marker of osteoclast function","volume":"34","author":"Minkin","year":"1982","journal-title":"Calcif Tissue Int"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1054\/bjoc.1999.1042","article-title":"Sensitization of tumour cells to lysis by virus-specific CTL using antibody-targeted MHC class I\/peptide complexes","volume":"82","author":"Ogg","year":"2000","journal-title":"Br J Cancer"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(00)00436-6","article-title":"Melanoma cells stimulate osteoclastogenesis, c-Src expression and osteoblast cytokines","volume":"37","author":"Perez","year":"2001","journal-title":"Eur J Cancer"},{"key":"B58","article-title":"Cellular and hormonal mechanisms associated with Malignant bone resorption","volume":"71","author":"Quinn","year":"1994","journal-title":"Lab Invest"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1242\/jcs.101.3.681","article-title":"Tumour infiltrating macrophages are capable of bone resorption","volume":"101","author":"Quinn","year":"1992","journal-title":"J Cell Sci"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.2000.15.8.1459","article-title":"Fibroblastic stromal cells express receptor activator of NF-kappa B ligand and support osteoclast differentiation","volume":"15","author":"Quinn","year":"2000","journal-title":"J Bone Miner Res"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-9896(199801)184:1<31::AID-PATH962>3.0.CO;2-V","article-title":"Human tumour-associated macrophages differentiate into osteoclastic bone-resorbing cells","volume":"184","author":"Quinn","year":"1998","journal-title":"J Pathol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.orthres.2004.10.006","article-title":"Arthroplasty membrane-derived fibroblasts directly induce osteoclast formation and osteolysis in aseptic loosening","volume":"23","author":"Sabokbar","year":"2005","journal-title":"J Orthop Res"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)80209-3","article-title":"Osteoprotegerin: a novel secreted protein involved in the regulation of bone density","volume":"89","author":"Simonet","year":"1997","journal-title":"Cell"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/s0959-8049(01)00445-2","article-title":"The role of the EORTC pathologist in clinical trials: achievements and perspectives. European Organisation for Research and Treatment of Cancer","volume":"38","author":"Spatz","year":"2002","journal-title":"Eur J Cancer"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1002\/path.1953","article-title":"Bone stromal cells in pagetic bone and Paget\u2019s sarcoma express RANKL and support human osteoclast formation","volume":"209","author":"Sun","year":"2006","journal-title":"J Pathol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1007\/s10753-020-01408-5","article-title":"Focal adhesion kinase activity and localization is critical for TNF-\u03b1-induced nuclear factor-\u03baB activation","volume":"44","author":"Murphy","year":"2021","journal-title":"Inflammation"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1038\/s41418-022-01071-3","article-title":"HSP90\u03b2 promotes osteoclastogenesis by dual-activation of cholesterol synthesis and NF-\u03baB signaling","volume":"30","author":"Cheng","year":"2023","journal-title":"Cell Death Differ"},{"key":"B68","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1042\/bj3340297","article-title":"Interleukin-6-type cytokine signalling through the gp130\/Jak\/STAT pathway","volume":"334","author":"Heinrich","year":"1998","journal-title":"Biochem J"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2016.04.061","article-title":"Artesunate obliterates experimental hepatocellular carcinoma in rats through suppression of IL-6-JAK-STAT signalling","volume":"82","author":"Ilamathi","year":"2016","journal-title":"BioMed Pharmacother"},{"key":"B70","doi-asserted-by":"publisher","first-page":"18711","DOI":"10.1038\/s41598-023-45496-3","article-title":"IL-8 is a novel prometastatic chemokine in intrahepatic cholangiocarcinoma that induces CXCR2-PI3K\/AKT signaling upon CD97 activation","volume":"13","author":"Meng","year":"2023","journal-title":"Sci Rep"},{"key":"B71","doi-asserted-by":"publisher","first-page":"111427","DOI":"10.1016\/j.biopha.2021.111427","article-title":"CXCL8 chemokine in ulcerative colitis","volume":"138","author":"Zhu","year":"2021","journal-title":"BioMed Pharmacother"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1002\/smll.202300578","article-title":"et al: A Biomimetic Peptide Functions as Specific Extracellular Matrix for Quiescence of Stem Cells against Intervertebral Disc Degeneration","volume":"19","author":"Li","year":"2023","journal-title":"Small"},{"key":"B73","doi-asserted-by":"publisher","first-page":"e70091","DOI":"10.1002\/jev2.70091","article-title":"Extracellular vesicles from prostate cancer-corrupted osteoclasts drive a chain reaction of inflammatory osteolysis and tumour progression at the bone metastatic site","volume":"14","author":"Tamura","year":"2025","journal-title":"J Extracell Vesicles"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25158163","article-title":"Balancing the scales: the dual role of interleukins in bone metastatic microenvironments","volume":"25","author":"Dawalibi","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B75","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.canlet.2016.01.005","article-title":"et al: MED27 promotes melanoma growth by targeting AKT\/MAPK and NF-\u03baB\/iNOS signaling pathways","volume":"373","author":"Tang","year":"2016","journal-title":"Cancer Lett"},{"key":"B76","doi-asserted-by":"publisher","first-page":"2742","DOI":"10.1038\/s41467-021-22953-z","article-title":"Ultraviolet light-induced collagen degradation inhibits melanoma invasion","volume":"12","author":"Budden","year":"2021","journal-title":"Nat Commun"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30388-2","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study","volume":"20","author":"Robert","year":"2019","journal-title":"Lancet Oncol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.1611","article-title":"Immune checkpoint inhibitors and immune-related adverse events in patients with advanced melanoma: A systematic review and network meta-analysis","volume":"3","author":"Chang","year":"2020","journal-title":"JAMA Netw Open"},{"key":"B79","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s13046-025-03396-6","article-title":"A novel pH-sensitive nanoparticles encapsulating anti-PD-1 antibody and MDK-siRNA overcome immune checkpoint blockade resistance in HCC via reshaping immunosuppressive TME","volume":"44","author":"Xu","year":"2025","journal-title":"J Exp Clin Cancer Res"},{"key":"B80","doi-asserted-by":"publisher","first-page":"7250","DOI":"10.1038\/s41467-022-34877-3","article-title":"A single-cell analysis reveals tumor heterogeneity and immune environment of acral melanoma","volume":"13","author":"Zhang","year":"2022","journal-title":"Nat Commun"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-3145","article-title":"single-cell characterization of the cellular landscape of acral melanoma identifies novel targets for immunotherapy","volume":"28","author":"Li","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B82","doi-asserted-by":"publisher","first-page":"2376782","DOI":"10.1080\/2162402X.2024.2376782","article-title":"Differential impact of genetic deletion of TIGIT or PD-1 on melanoma-specific T-lymphocytes","volume":"13","author":"Cadiou","year":"2024","journal-title":"Oncoimmunology"},{"key":"B83","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.canlet.2021.10.034","article-title":"Wnt signaling pathway in cancer immunotherapy","volume":"525","author":"Zhou","year":"2022","journal-title":"Cancer Lett"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30494-0","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial","volume":"21","author":"Ascierto","year":"2020","journal-title":"Lancet Oncol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pathol-042020-042741","article-title":"Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance","volume":"16","author":"Bagchi","year":"2021","journal-title":"Annu Rev Pathol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01723-1","article-title":"Nivolumab plus relatlimab: first approval","volume":"82","author":"Paik","year":"2022","journal-title":"Drugs"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-22-0057","article-title":"Preclinical characterization of relatlimab, a human LAG-3-blocking antibody, alone or in combination with nivolumab","volume":"10","author":"Thudium","year":"2022","journal-title":"Cancer Immunol Res"},{"key":"B88","doi-asserted-by":"publisher","first-page":"e2002104","DOI":"10.1002\/adhm.202002104","article-title":"Immune checkpoint inhibitor-based strategies for synergistic cancer therapy","volume":"10","author":"He","year":"2021","journal-title":"Adv Healthc Mater"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-019-0530-6","article-title":"Patterns of response with talimogene laherparepvec in combination with ipilimumab or ipilimumab alone in metastatic unresectable melanoma","volume":"121","author":"Chesney","year":"2019","journal-title":"Br J Cancer"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-021-01486-8","article-title":"Impact of prior treatment with immune checkpoint inhibitors on dacarbazine efficacy in metastatic melanoma","volume":"125","author":"Bouchereau","year":"2021","journal-title":"Br J Cancer"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.7150\/jca.72210","article-title":"Efficacy and safety of immune checkpoint inhibitors for advanced Malignant melanoma: A meta-analysis on monotherapy vs combination therapy","volume":"13","author":"Pradeep","year":"2022","journal-title":"J Cancer"},{"key":"B92","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1158\/2326-6066.CIR-17-0356","article-title":"Robust antitumor responses result from local chemotherapy and CTLA-4 blockade","volume":"6","author":"Ariyan","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13040678","article-title":"Enhance the immune checkpoint inhibitors efficacy with radiotherapy induced immunogenic cell death: A comprehensive review and latest developments","volume":"13","author":"Procureur","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14174069","article-title":"Efficacy of large use of combined hypofractionated radiotherapy in a cohort of anti-PD-1 monotherapy-treated melanoma patients","volume":"14","author":"Saiag","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-2452","article-title":"ipilimumab and radiation in patients with high-risk resected or regionally advanced melanoma","volume":"27","author":"Salama","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B96","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1016\/j.ccell.2021.07.023","article-title":"Anti-PD-1\/L1 lead-in before MAPK inhibitor combination maximizes antitumor immunity and efficacy","volume":"39","author":"Wang","year":"2021","journal-title":"Cancer Cell"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-1630","article-title":"BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma","volume":"19","author":"Frederick","year":"2013","journal-title":"Clin Cancer Res"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30934-X","article-title":"Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF(V600) mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial","volume":"395","author":"Gutzmer","year":"2020","journal-title":"Lancet"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1608215\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T05:18:44Z","timestamp":1756271924000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1608215\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,27]]},"references-count":98,"alternative-id":["10.3389\/fimmu.2025.1608215"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1608215","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,27]]},"article-number":"1608215"}}